Herbal Monograph
Goldenseal
Hydrastis canadensis L.
Ranunculaceae (Buttercup family)
Premier mucous membrane trophorestorative and antimicrobial bitter for catarr...
Overview
Plant Description
Low-growing herbaceous perennial, 15-50 cm tall, arising from a thick, knotty, horizontal rhizome that is bright yellow internally (the 'golden seal' of the common name). The rhizome is 1-6 cm long, 5-15 mm in diameter, with numerous thin rootlets arising from the lower surface and prominent bud scars on the upper surface. Stem single, erect, unbranched, hairy, bearing a single large basal leaf on a long petiole and two smaller sessile or short-petioled cauline leaves near the summit. Basal leaf palmate, 12-30 cm wide, with 5-7 deeply cut, doubly serrate lobes, prominently veined, wrinkled, and hairy on both surfaces. Cauline leaves similar but smaller, 3-5 lobed. Flower solitary, terminal, small (approximately 1 cm diameter), appearing in late spring (April-May); it has no petals but possesses three small, greenish-white, caducous sepals that fall at anthesis, leaving a brush-like cluster of numerous (40-50) greenish-white stamens surrounding 5-15 separate pistils. Fruit a cluster of small, bright crimson berries resembling a raspberry (hence 'ground raspberry'), each berry containing 1-2 hard, shiny black seeds. The entire plant has a strongly bitter taste and a distinctive odor when fresh.
Habitat
Grows in rich, moist, well-drained deciduous forests with deep humus soils. Prefers partial to full shade under a dense canopy of hardwoods such as sugar maple, beech, basswood, oak, and tulip poplar. Requires circumneutral to slightly alkaline soils (pH 6.0-7.5), often over calcareous bedrock (limestone, dolostone). Thrives in mesic cove forests, ravines, north-facing slopes, and rich bottomland forests. Sensitive to disturbance of the canopy and soil; populations decline when forest cover is removed or when the understory is heavily disturbed by invasive species such as garlic mustard (Alliaria petiolata) or by deer overpopulation.
Distribution
Native to eastern North America. Range extends from southern Vermont and southwestern Quebec south through the Appalachian Mountains to northern Georgia and Alabama, and west to Arkansas, Missouri, Iowa, Minnesota, and Wisconsin. Historically most abundant in the Ohio River Valley, southern Appalachians, and the Ozark Plateau. The species is now rare or extirpated in many peripheral parts of its range due to overharvesting and habitat loss. Listed as endangered or threatened in multiple US states including Connecticut, Georgia, Maine, Massachusetts, Minnesota, New Jersey, and North Carolina. In Canada, assessed as of special concern by COSEWIC and listed as threatened in Ontario.
Parts Used
Rhizome and root (Hydrastis rhizoma)
Preferred: Dried rhizome and root for decoction, tincture, and powdered capsules; dried powder for topical applications
The dried rhizome and attached roots constitute the official drug in all major pharmacopeial and monograph references (USP, BHP, AHP, ESCOP). The rhizome is the primary source of the pharmacologically active isoquinoline alkaloids: berberine, hydrastine, and canadine. The USP specifies minimum alkaloid content of not less than 2.0% hydrastine and not less than 2.5% berberine. The bright yellow color of the rhizome cross-section is due to berberine and serves as a crude quality indicator. Rhizomes from wild-simulated or forest-farmed plants generally have equivalent or superior alkaloid content compared to field-cultivated material.
Leaf (aerial parts)
Preferred: Not commonly used as a standalone preparation; research interest only
Aerial parts contain lower concentrations of berberine, hydrastine, and canadine compared to the rhizome and do not meet pharmacopeial alkaloid content requirements. However, research by Tims et al. (2006) and Junio et al. (2011) demonstrated that aerial portions of goldenseal contain efflux pump inhibitors (not the major alkaloids themselves) that synergistically enhance the antibacterial activity of berberine against Staphylococcus aureus. This suggests the aerial parts have unique pharmacological value not captured by alkaloid content alone. Not included in any pharmacopeial monograph as an official drug part.
Key Constituents
Isoquinoline alkaloids
The isoquinoline alkaloid fraction — primarily berberine and hydrastine — is responsible for the majority of goldenseal's pharmacological activity. Berberine provides the antimicrobial, bitter tonic, and metabolic effects, while hydrastine contributes astringent, vasoconstrictive, and mucous membrane tonic activity. The combination of these two alkaloids with distinct but complementary mechanisms of action distinguishes goldenseal from other berberine-containing plants (Coptis, Berberis, Mahonia). The alkaloid fraction also drives the clinically relevant CYP450 drug interactions and the pregnancy contraindication.
Non-alkaloid phenolic compounds
Non-alkaloid phenolics contribute ancillary antioxidant and anti-inflammatory effects but are not considered primary drivers of goldenseal's therapeutic activity.
Volatile oil and resinous compounds
The volatile and resinous fraction is not a significant contributor to goldenseal's pharmacological activity. Unlike many other medicinal herbs, goldenseal's therapeutic profile is driven almost entirely by its alkaloid content.
Other constituents
Minor constituents providing nutritive value but not considered significant drivers of therapeutic action.
Herbal Actions
Goldenseal's most distinctive and clinically important action in Western herbalism. It restores tone, reduces excessive secretion, and heals damaged mucous membranes throughout the body — oral, gastric, intestinal, respiratory, and genitourinary. This action combines the astringent vasoconstriction of hydrastine with the antimicrobial activity of berberine and the bitter tonic stimulation of digestive secretions. The Eclectic physicians specifically described goldenseal as exerting 'a peculiar influence upon the mucous tissues, imparting tone when relaxed, and restraining undue secretion.' This trophorestorative action is the basis for goldenseal's traditional use in catarrhal states of all mucous surfaces.
[3, 4, 6, 15]Kills or inhibits the growth of microorganisms
Broad-spectrum antimicrobial activity demonstrated in vitro against Gram-positive bacteria (Staphylococcus aureus including MRSA, Streptococcus spp.), some Gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae), fungi (Candida albicans), and protozoa (Entamoeba histolytica, Giardia lamblia). Berberine is the principal antimicrobial compound, intercalating into bacterial DNA and inhibiting protein synthesis. Importantly, goldenseal whole extracts are more active than isolated berberine against some organisms, due to synergistic efflux pump inhibition by non-alkaloid constituents. However, berberine's poor oral bioavailability means that systemic antimicrobial activity after oral dosing is limited; antimicrobial effects are most relevant topically and in the GI lumen.
[3, 4, 11, 12, 13]Intensely bitter taste stimulates salivary, gastric, and biliary secretions via the cephalic phase digestive reflex and direct bitter receptor activation. Promotes appetite, improves digestive function, and enhances hepatobiliary output. Goldenseal is classified as a simple bitter with additional cholagogue and choleretic properties. This action is most pronounced when goldenseal is taken in liquid form (tincture, decoction) where the bitter taste is perceived directly.
[3, 4, 6]Reduces inflammation
Berberine demonstrates anti-inflammatory activity through inhibition of NF-kB signaling, suppression of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), and inhibition of COX-2 expression. Anti-inflammatory effects are relevant both topically (mucous membranes, skin) and in the gastrointestinal tract. Hydrastine contributes anti-inflammatory effects via vasoconstriction and reduction of edema at inflamed mucosal surfaces.
[4, 14]Stimulates bile production (choleretic) and promotes bile flow from the gallbladder (cholagogue). This action is attributed to the bitter alkaloid fraction, particularly berberine, which has demonstrated choleretic activity in animal studies. Supports fat digestion and hepatic detoxification. Traditionally used for jaundice and sluggish hepatobiliary function.
[3, 15]Tightens and tones tissue, reduces secretions
Hydrastine produces vasoconstriction and reduction of mucous membrane blood flow, which contributes to the drying and toning of boggy, swollen, or catarrhal mucous membranes. This astringent action is distinct from the tannin-based astringency of herbs like oak bark or cranesbill; in goldenseal, it is alkaloid-mediated. Useful for excessive mucous discharge from any mucosal surface.
[3, 6, 15]Hydrastine and canadine have demonstrated uterine-stimulant activity in vitro and in animal studies, increasing the tone and contractility of uterine smooth muscle. This pharmacological action underlies the AHPA Class 2b contraindication during pregnancy. At standard therapeutic doses, the clinical significance of this action outside of pregnancy is limited, but it historically informed use as a postpartum hemostatic and for menorrhagia.
[5, 7, 15]Berberine demonstrates immunomodulatory effects in vitro and in animal models, including enhancement of macrophage phagocytic activity and modulation of inflammatory cytokine production. Clinical significance at standard oral goldenseal doses is uncertain due to berberine's limited systemic bioavailability. Topical and GI-lumen immunomodulatory effects may be more clinically relevant than systemic effects.
[4]Therapeutic Indications
gastrointestinal
Dyspepsia, gastritis, and peptic conditions
ESCOP-approved indication for digestive disorders and dyspeptic complaints. Goldenseal's bitter tonic and anti-inflammatory actions improve digestive secretion, reduce gastric mucosal inflammation, and promote healing of damaged mucosal tissue. Berberine has demonstrated activity against Helicobacter pylori in vitro. Used as tincture or decoction before meals. The BHP lists specific indications for 'catarrhal gastritis, dyspepsia, and gastric catarrh.'
[2, 3, 4, 6]Infectious diarrhea (bacterial, protozoal)
Berberine has demonstrated clinical efficacy in multiple RCTs for acute infectious diarrhea caused by Vibrio cholerae, Escherichia coli, Giardia lamblia, and Entamoeba histolytica. However, most clinical trials used isolated berberine, not whole goldenseal preparations. The localized antimicrobial action of berberine in the GI lumen (where it achieves high concentrations due to poor systemic absorption) provides a pharmacological rationale for goldenseal's traditional use in diarrheal diseases. The astringent action of hydrastine further reduces excessive intestinal secretion.
[3, 4, 14]Inflammatory bowel conditions (colitis, irritable bowel with diarrhea)
Traditional use for chronic intestinal inflammation with mucous discharge. The combination of anti-inflammatory, antimicrobial, and mucous membrane restorative actions provides a strong therapeutic rationale. However, controlled clinical trials using goldenseal specifically (rather than isolated berberine) for IBD are lacking.
[3, 15]Respiratory System
Chronic catarrhal conditions of the upper respiratory tract (sinusitis, post-nasal drip, chronic rhinitis)
One of the most widely cited traditional indications. Goldenseal's astringent and antimicrobial actions dry excessive mucous secretion and address secondary bacterial infection in chronically inflamed sinuses and nasal passages. Used internally (tincture, capsule) and as a topical nasal wash (diluted decoction or saline with goldenseal tincture). Hoffmann specifically recommends goldenseal for 'catarrhal states of the mucous membranes' of the upper respiratory tract.
[3, 6, 15]Sore throat, pharyngitis, and tonsillitis
Used as a gargle (diluted tincture or cooled decoction) for sore throat, pharyngitis, and oral mucosal inflammation. Combines antimicrobial, anti-inflammatory, and astringent actions topically on inflamed pharyngeal mucosa. Often combined with sage (Salvia officinalis) or myrrh (Commiphora molmol) in gargle formulas.
[3, 6]oral
Stomatitis, gingivitis, and oral ulceration
Applied topically as a mouthwash or rinse (diluted tincture, 5-10 drops in a small amount of water) for inflamed gums, mouth ulcers, and oral mucositis. The antimicrobial and astringent actions reduce bacterial load and promote mucosal healing. The Eclectic physicians particularly valued goldenseal for oral thrush (Candida).
[3, 6, 15]genitourinary
Vaginal infections and leucorrhea
Traditional use as a douche (diluted decoction or diluted tincture) for vaginal infections including Candida vulvovaginitis and cervicitis with excessive discharge. Berberine has demonstrated anti-Candida activity in vitro. The mucous membrane restorative action addresses the underlying tissue laxity and excessive secretion. External use only for this indication.
[3, 6]Menorrhagia (excessive menstrual bleeding)
Hydrastine's vasoconstrictive and uterotonic actions reduce excessive menstrual bleeding. Used traditionally as part of formulas for menorrhagia, not typically as a single herb. The Eclectic physicians valued goldenseal (often combined with Trillium erectum or Viburnum prunifolium) for uterine hemorrhage and excessive menstrual flow.
[3, 15]Hepatobiliary System
Sluggish hepatobiliary function, biliary insufficiency, jaundice
Cholagogue and choleretic actions stimulate bile production and flow. Used traditionally for jaundice, hepatic congestion, and biliary stasis. Berberine has demonstrated choleretic activity in animal models. Combined with other hepatobiliary herbs (dandelion root, artichoke leaf, milk thistle) in clinical practice.
[3, 15]Skin / Integumentary
Minor skin infections, wounds, and inflammatory skin conditions
Applied topically as a wash (diluted decoction or diluted tincture), poultice, or ointment for infected wounds, skin ulcers, eczema, and dermatitis. Berberine's antimicrobial activity and the anti-inflammatory effects of the whole extract support topical wound care. Used traditionally by Cherokee and other Indigenous peoples as a wash for skin diseases and sore eyes.
[3, 6, 15]ophthalmic
Conjunctivitis and eye inflammation (topical wash)
One of goldenseal's oldest traditional uses — hence the common names 'eye balm' and 'eye root.' Used historically by Indigenous peoples and Eclectic physicians as a dilute eyewash for conjunctivitis, blepharitis, and eye inflammation. Berberine has demonstrated antimicrobial activity relevant to common conjunctival pathogens. Modern use requires proper sterile preparation of the eyewash to avoid contamination. Clinical trial evidence specifically for goldenseal eyewash preparations is absent.
[3, 15]Energetics
Temperature
cold
Moisture
dry
Taste
Tissue States
damp/stagnation, hot/excitation, lax/atony
Goldenseal is cold and dry in Western energetic assessment. Its intense bitterness and cooling quality make it specific for hot, damp, boggy tissue states with excess secretion — the classic 'relaxed, catarrhal mucous membrane' of the Eclectic tradition. It is contraindicated (energetically) in cold, dry, atrophic conditions where mucous membranes are already thin, pale, and under-secreting. Hoffmann and other Western herbalists emphasize that goldenseal is NOT a general-purpose immune stimulant or 'herbal antibiotic' despite popular misconception. Its specific niche is the restoration of tone to lax, congested, and over-secreting mucous membranes. The cold, dry energetics also indicate why goldenseal should generally be used for short courses (2-4 weeks) rather than as a long-term tonic — prolonged use may overly dry and cool the digestive system.
Traditional Uses
Native American traditional medicine
- Wash for skin diseases and sore eyes (Cherokee)
- Root powder mixed with bear fat as insect repellent (Cherokee)
- Treatment for digestive complaints and liver conditions (Iroquois)
- Yellow dye for clothing, body paint, and weapons (multiple nations)
- General tonic and bitter digestive aid
- Treatment for mouth and throat sores
"At the time of European colonization of the Americas, goldenseal was in extensive use among certain Native American tribes of North America, both as a medicine and as a coloring material. Benjamin Smith Barton (1798) first called attention to Cherokee use of goldenseal as a cancer treatment and as a wash for sore eyes. The Iroquois used it for whooping cough, diarrhea, liver problems, and fever. The Cherokee used the root as a wash for skin diseases and sore eyes, and mixed a powder from the root with bear fat for insect repellent."
Eclectic medicine (American, 19th-20th century)
- Mucous membrane tonic for all catarrhal conditions
- Digestive bitter and stomachic for dyspepsia and gastric catarrh
- Treatment for chronic gonorrhea and leucorrhea
- Topical wash for indolent ulcers and ophthalmia
- Treatment for jaundice and hepatic congestion
- Uterine tonic for menorrhagia and post-partum hemorrhage
- Gargle for sore throat and oral ulceration
"Felter and Lloyd (King's American Dispensatory, 1898): 'Hydrastis exerts a peculiar influence upon the mucous tissues, and upon the circulatory system. Upon the mucous membranes it imparts tone when relaxed, and restrains undue secretion... It is a slow but efficient alterative in gastric and intestinal catarrhal states, with tendency to constipation, debility, and feeble appetite... It is valuable in all chronic forms of catarrh, with free discharge — nasal, pharyngeal, bronchial, gastric, intestinal, vesical, urethral, and vaginal.' The Eclectics specifically emphasized goldenseal's action on 'relaxed' (atonic) mucous membranes with excessive secretion, distinguishing this indication from acute inflammatory states."
[15]
Western clinical herbalism (contemporary)
- Catarrhal conditions of mucous membranes (sinusitis, post-nasal drip, chronic rhinitis)
- Digestive bitter for dyspepsia, gastritis, and poor appetite
- GI infections and infectious diarrhea
- Topical antimicrobial for skin wounds, mouth ulcers, and vaginal infections
- Hepatobiliary tonic for sluggish digestion and biliary insufficiency
- Gargle for sore throat and tonsillitis
"Hoffmann (2003): 'Goldenseal is one of the most useful herbs available to us. It owes most of its popularity to its action on the mucous membranes of the body... Where there is congestion and excessive catarrhal discharge, goldenseal will prove invaluable... As a bitter it stimulates the appetite and aids digestion.' Hoffmann specifically cautions that goldenseal's reputation as a 'herbal antibiotic' is misleading and that its primary value is as a mucous membrane trophorestorative, not as a systemic antimicrobial."
[3]
ESCOP phytotherapy
- Digestive disorders and dyspeptic complaints
- Gastritis
- Catarrhal conditions of the upper respiratory tract
"The ESCOP monograph on Hydrastis rhizoma (2013) supports the therapeutic use of goldenseal rhizome for digestive disorders, dyspeptic complaints, and gastritis, based on the pharmacological evidence for its bitter, anti-inflammatory, and antimicrobial properties."
[2]
Modern Research
Commission E evaluation
The German Commission E did NOT issue an approval monograph for goldenseal.
Findings: The German Commission E did not approve Hydrastis canadensis. This is notable because goldenseal is widely used in North American herbalism and is approved or monographed by other authorities (ESCOP, AHP, BHP). The Commission E's non-approval does not constitute a negative monograph (declaring the herb ineffective or unsafe); rather, it means the herb was not evaluated or that insufficient evidence was submitted at the time of review. The Commission E's coverage was primarily of herbs in the European tradition, and goldenseal as a North American native plant was not a priority for evaluation.
Limitations: The absence of a Commission E monograph reflects the timing and scope of the Commission E process (primarily 1978-1994) and European regulatory priorities, not a negative assessment of goldenseal's efficacy or safety.
[1]
Antimicrobial synergy and efflux pump inhibition
Goldenseal extracts contain efflux pump inhibitors that synergistically enhance berberine's antibacterial activity.
Findings: Stermitz et al. (2000) first demonstrated that berberine-producing plants also produce bacterial efflux pump inhibitors (specifically 5'-methoxyhydnocarpin) that prevent bacteria from pumping berberine out of the cell, dramatically increasing its effective antimicrobial concentration. Junio et al. (2011) extended this work specifically to H. canadensis, showing that the aerial parts of goldenseal (not the root) contain efflux pump inhibitors that synergistically enhance berberine's activity against S. aureus. The three major alkaloids (berberine, hydrastine, canadine) were NOT responsible for the efflux pump inhibition — the active compounds are non-alkaloid constituents of the aerial parts. This research provides a compelling scientific rationale for whole-plant use and demonstrates that goldenseal's antimicrobial activity cannot be fully explained by berberine content alone.
Limitations: In vitro studies. The efflux pump inhibitors have been identified in the aerial parts but not in the rhizome (the official drug part). Clinical significance of efflux pump inhibition at achievable in vivo concentrations is not established.
Antimicrobial activity against MRSA
In vitro evaluation of goldenseal extracts against methicillin-resistant Staphylococcus aureus.
Findings: Cech et al. (2012) evaluated goldenseal extracts for quorum quenching and antimicrobial activity against MRSA. Goldenseal extracts inhibited bacterial growth and interfered with quorum sensing mechanisms that regulate virulence factor production in S. aureus. This suggests goldenseal may attenuate MRSA pathogenicity through multiple mechanisms beyond direct bactericidal action.
Limitations: In vitro study. MIC values for goldenseal extracts against MRSA were substantially higher than conventional antibiotics. Clinical relevance as adjunctive therapy is plausible but unproven.
[13]
CYP450 enzyme inhibition and drug interactions
Clinical pharmacokinetic studies demonstrating goldenseal's inhibition of cytochrome P450 enzymes CYP3A4 and CYP2D6.
Findings: Gurley et al. (2005, 2008) conducted clinical pharmacokinetic studies demonstrating that goldenseal supplementation (900 mg three times daily for 14 days) significantly inhibits CYP3A4/5 activity (approximately 40% reduction) and CYP2D6 activity (approximately 40% reduction) in healthy volunteers. CYP1A2 and CYP2E1 were not significantly affected. The mechanism involves formation of a metabolic intermediate complex (MIC) between the methylenedioxyphenyl moiety of hydrastine and CYP3A4 heme iron, producing time-dependent (mechanism-based) inhibition — a persistent effect that outlasts the presence of the inhibitor. This mechanism is similar to that of grapefruit juice (furanocoumarins) and represents a clinically significant herb-drug interaction risk.
Limitations: Studies used relatively high doses of goldenseal (2,700 mg/day for 14 days). The magnitude of CYP inhibition at lower, more typical therapeutic doses is less well characterized. The degree of intestinal vs. hepatic CYP3A4 inhibition has not been fully delineated.
NTP toxicology and carcinogenicity study
Two-year National Toxicology Program feeding study evaluating goldenseal root powder carcinogenicity in rodents.
Findings: The NTP Technical Report 562 (2010) reported the results of 2-year feed studies of goldenseal root powder in F344/N rats and B6C3F1 mice. There was 'clear evidence of carcinogenic activity' in male rats (increased hepatocellular adenoma and carcinoma) and female rats (increased hepatocellular adenoma), and 'some evidence of carcinogenic activity' in male mice (increased hepatoblastoma and hepatocellular adenoma). Doses tested were high (2,500-25,000 ppm in feed, equivalent to approximately 200-2,000 mg/kg/day). The relevance of these high-dose rodent findings to human therapeutic use at standard doses remains debated.
Limitations: Doses used in the NTP study were far in excess of typical human therapeutic doses (equivalent to approximately 10-100 times standard human daily doses on a mg/kg basis). The study used goldenseal root powder administered in feed, which differs from typical human preparations (tincture, decoction). Rodent hepatocarcinogenesis models do not always predict human risk. No epidemiological data link goldenseal use at standard doses to liver cancer in humans. However, these findings warrant prudent short-term use (2-4 weeks) rather than chronic administration, consistent with traditional practice.
[10]
Berberine in type 2 diabetes and metabolic syndrome
Meta-analyses of randomized controlled trials evaluating berberine for glycemic and lipid parameters in type 2 diabetes.
Findings: Multiple systematic reviews and meta-analyses have demonstrated that isolated berberine (typically 0.9-1.5 g/day) significantly reduces fasting plasma glucose, HbA1c, triglycerides, total cholesterol, and LDL cholesterol in patients with type 2 diabetes or metabolic syndrome. Berberine's mechanisms include AMPK activation, enhancement of glucose uptake in peripheral tissues, and promotion of lipid metabolism. NOTE: These trials used purified berberine, NOT whole goldenseal preparations. The berberine dose used in these trials (900-1500 mg/day) far exceeds the berberine content of standard goldenseal doses (a typical goldenseal tincture dose of 2-4 mL delivers approximately 10-40 mg berberine). Therefore, these metabolic findings cannot be directly attributed to goldenseal and should not be used to promote goldenseal for diabetes.
Limitations: Studies used isolated berberine, not whole goldenseal. Berberine doses in trials greatly exceed what is delivered by standard goldenseal preparations. Many trials were conducted in Chinese populations using berberine from Coptis chinensis. Extrapolation to goldenseal use for metabolic conditions is scientifically inappropriate without direct clinical evidence.
[14]
Preparations & Dosage
Tincture
Strength: 1:5 dried rhizome/root in 60% ethanol (BHP specification)
Macerate dried goldenseal rhizome and root in 60% ethanol at a ratio of 1:5 for 2-4 weeks, shaking daily. Press and filter through cheesecloth and fine filter. The resulting tincture should be deeply yellow-orange in color.
1-2 mL of 1:5 tincture (in 60% ethanol), 3 times daily. Some sources cite up to 4 mL three times daily for acute conditions.
3 times daily, taken 15-30 minutes before meals to maximize bitter tonic effect
Short-term use: 2-4 weeks maximum, then reassess. Do not use continuously for extended periods.
Not generally recommended for children under 12 years. If used under practitioner supervision for children over 6 years, use one-quarter to one-half adult dose.
Tincture is the most commonly used preparation in contemporary Western herbalism. The high ethanol percentage (60%) is needed to extract the alkaloid fraction efficiently. Lower ethanol concentrations will under-extract berberine and hydrastine. Liquid tincture form is preferred over capsules when the bitter tonic action on digestion is desired, as the bitter taste triggers the cephalic phase digestive response. Tincture is also used diluted as a topical wash, gargle, or mouthwash.
Decoction
Strength: 0.5-1 g dried rhizome per 250 mL water
Place 0.5-1 g (approximately one-half to one teaspoon) of dried, coarsely powdered goldenseal rhizome and root in 250 mL of cold water. Bring to a boil, reduce heat, and simmer gently (covered) for 10-15 minutes. Strain while hot.
0.5-1 g dried rhizome per cup, 3 times daily
3 times daily before meals
2-4 weeks maximum
Not generally recommended for children under 12 years
Decoction is the traditional preparation method for the tough, woody rhizome. Simmering (rather than simple infusion) is necessary to extract alkaloids from the dense plant material. The resulting decoction is intensely bitter and bright yellow. Decoction can be cooled and used as a topical wash for skin conditions, an eyewash (must be sterile-filtered), a gargle for sore throat, or a douche for vaginal conditions.
capsule/powder
Strength: 500-1000 mg dried rhizome powder per capsule dose; standardized extracts variable
Fill capsules with finely powdered dried goldenseal rhizome and root, or use commercially standardized capsules.
500-1000 mg dried rhizome powder, 3 times daily (equivalent to 1.5-3 g per day). Standardized extracts are sometimes standardized to 5% total alkaloids or 8-12% berberine content — follow manufacturer dosing for standardized products.
3 times daily with meals or as directed by practitioner
2-4 weeks maximum
Not recommended for children under 12 years
Capsules bypass the bitter taste, which is convenient but eliminates the cephalic-phase bitter tonic effect on digestion. When the primary therapeutic goal is bitter digestive stimulation, tincture or decoction is preferred. Capsules are suitable when the primary goal is antimicrobial action in the GI tract or systemic alkaloid delivery. Adulteration of goldenseal products is well-documented — the American Botanical Council's Botanical Adulterants Prevention Program has identified substitution with Coptis chinensis or addition of purified berberine to low-quality goldenseal as common adulterant practices.
topical
Strength: Decoction: 0.5-1 g per 250 mL. Diluted tincture: 1:3 to 1:5 tincture-to-water ratio. Ointment: 5-10% goldenseal.
For topical wash: Prepare a decoction as above and allow to cool. Use as a wound wash, eye wash (sterile-filtered only), or compress. Alternatively, dilute tincture 1:3 to 1:5 with water or saline for topical application. For ointment: incorporate powdered goldenseal rhizome or goldenseal tincture into a suitable ointment base at 5-10% concentration.
Apply to affected area 2-3 times daily as needed
2-3 times daily or as needed
Until healing is achieved; reassess if no improvement within 1-2 weeks
Topical use suitable for children over 2 years under practitioner supervision
Topical application delivers berberine and hydrastine directly to the site of action (skin, mucous membranes) and avoids systemic bioavailability limitations. Topical use is appropriate for wound care, skin infections, oral mucosal conditions (gargle, mouthwash), conjunctivitis (sterile-filtered eyewash only), and vaginal infections (dilute douche). The yellow staining of berberine on skin and clothing is harmless but cosmetically undesirable and should be communicated to patients.
Safety & Interactions
Class 2b
Not to be used during lactation (AHPA Botanical Safety Handbook)
Contraindications
AHPA Class 2b: 'Not to be used during pregnancy.' Hydrastine and canadine have demonstrated uterotonic (oxytocic) activity — they stimulate uterine smooth muscle contraction. This poses a theoretical risk of premature labor or miscarriage. Berberine has also shown uterine-stimulant effects in animal models. Although clinical cases of goldenseal-induced miscarriage are not documented in the modern literature, the pharmacological evidence is sufficient to maintain pregnancy as an absolute contraindication. This is the consensus position of the AHPA, Brinker, Mills & Bone, and all major herbal safety references.
Some sources list goldenseal as contraindicated in severe hypertension based on older reports that hydrastine has vasoconstrictive and hypertensive activity. The clinical significance at standard oral doses is debated; Mills & Bone (2013) consider this a theoretical concern rather than a documented clinical risk. However, caution is warranted, particularly at higher doses.
Berberine can displace bilirubin from albumin binding sites, theoretically worsening neonatal jaundice (kernicterus risk). Oral goldenseal preparations should not be administered to neonates or infants.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| CYP3A4 substrates (e.g., cyclosporine, tacrolimus, many statins, calcium channel blockers, protease inhibitors, benzodiazepines, macrolide antibiotics) (CYP3A4 substrates) | moderate | Hydrastine produces time-dependent (mechanism-based) inhibition of CYP3A4 via metabolic intermediate complex formation with the enzyme's heme iron. This is a persistent inhibitory effect — unlike competitive inhibition, mechanism-based inhibition requires synthesis of new enzyme to restore activity. Clinical studies demonstrate approximately 40% reduction in CYP3A4/5 activity after goldenseal supplementation. |
| CYP2D6 substrates (e.g., codeine, dextromethorphan, many antidepressants, some antipsychotics, some beta-blockers, tamoxifen) (CYP2D6 substrates) | moderate | Goldenseal inhibits CYP2D6 activity by approximately 40% in clinical studies. Berberine appears to be the primary contributor to CYP2D6 inhibition. |
| Anticoagulant/antiplatelet medications (Anticoagulants) | theoretical | Berberine has demonstrated antiplatelet activity in vitro. Theoretical additive effect with anticoagulant and antiplatelet drugs. |
| Antihypertensive medications (Antihypertensives) | theoretical | Conflicting pharmacological data: berberine has demonstrated vasodilatory and hypotensive effects, while hydrastine has vasoconstrictive properties. The net effect on blood pressure at standard goldenseal doses is uncertain. |
| Hypoglycemic agents (insulin, metformin, sulfonylureas) (Antidiabetics) | theoretical | Berberine at high doses (900-1500 mg/day as isolated compound) has demonstrated glucose-lowering activity. Standard goldenseal doses deliver much less berberine, but an additive hypoglycemic effect is theoretically possible. |
Pregnancy & Lactation
Pregnancy
unsafe
Lactation
insufficient data
PREGNANCY: Contraindicated (AHPA Class 2b). Hydrastine and canadine have demonstrated uterotonic activity. Berberine also shows uterine-stimulant effects in animal models. The oxytocic alkaloid fraction poses a theoretical risk of premature labor or miscarriage. All major herbal safety references agree on this contraindication. LACTATION: Insufficient data. Berberine may pass into breast milk. Given the theoretical risk of neonatal jaundice exacerbation (berberine displaces bilirubin from albumin) and the lack of safety data during lactation, goldenseal should be avoided during breastfeeding or used only under experienced practitioner supervision.
Adverse Effects
References
Monograph Sources
- [1] Blumenthal, M., Busse, W.R., Goldberg, A., et al.. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council / Integrative Medicine Communications (1998) . ISBN: 978-0965555500
- [2] ESCOP (European Scientific Cooperative on Phytotherapy). ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products — Hydrastis rhizoma (Goldenseal rhizome). ESCOP / Thieme (2013) . ISBN: 978-1901964073
- [3] Hoffmann, D.. Medical Herbalism: The Science and Practice of Herbal Medicine. Healing Arts Press (2003) . ISBN: 978-0892817498
- [4] Mills, S., Bone, K.. Principles and Practice of Phytotherapy: Modern Herbal Medicine (2nd edition). Churchill Livingstone / Elsevier (2013) . ISBN: 978-0443069925
- [5] Gardner, Z., McGuffin, M. (eds.). American Herbal Products Association's Botanical Safety Handbook (2nd edition). CRC Press (2013) . ISBN: 978-1466516946
- [6] British Herbal Medicine Association. British Herbal Pharmacopoeia. BHMA (1983)
- [7] Brinker, F.. Herbal Contraindications and Drug Interactions (4th edition). Eclectic Medical Publications (2010) . ISBN: 978-1888483147
Clinical Studies
- [8] Gurley, B.J., Gardner, S.F., Hubbard, M.A., et al.. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clinical Pharmacology & Therapeutics (2005) ; 77 : 415-426 . DOI: 10.1016/j.clpt.2005.01.009 . PMID: 15900287
- [9] Gurley, B.J., Swain, A., Hubbard, M.A., et al.. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Molecular Nutrition & Food Research (2008) ; 52 : 755-763 . DOI: 10.1002/mnfr.200600300 . PMID: 18214850
- [10] National Toxicology Program. Toxicology and Carcinogenesis Studies of Goldenseal Root Powder (Hydrastis canadensis) in F344/N Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program Technical Report Series (2010) ; 562 : 1-188 . PMID: 21372858
- [11] Stermitz, F.R., Lorenz, P., Tawara, J.N., et al.. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proceedings of the National Academy of Sciences USA (2000) ; 97 : 1433-1437 . DOI: 10.1073/pnas.030540597 . PMID: 10677479
- [12] Junio, H.A., Sy-Cordero, A.A., Ettefagh, K.A., et al.. Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis). Journal of Natural Products (2011) ; 74 : 1621-1629 . DOI: 10.1021/np200336g . PMID: 21661738
- [13] Cech, N.B., Junio, H.A., Ackermann, L.W., et al.. Quorum quenching and antimicrobial activity of goldenseal (Hydrastis canadensis) against methicillin-resistant Staphylococcus aureus (MRSA). Planta Medica (2012) ; 78 : 1556-1561 . DOI: 10.1055/s-0032-1315042 . PMID: 22814821
- [14] Abdel-Haq, H.. Goldenseal (Hydrastis canadensis L.) and its active constituents: A critical review of their efficacy and toxicological issues. Pharmacological Research (2020) ; 160 : 105085 . DOI: 10.1016/j.phrs.2020.105085 . PMID: 32683037
Traditional Texts
- [15] Felter, H.W., Lloyd, J.U.. King's American Dispensatory (18th edition, 3rd revision). Ohio Valley Company (1898)
- [16] Barton, B.S.. Collections for an Essay Towards a Materia Medica of the United-States. Philadelphia (1798)
- [17] Moerman, D.E.. Native American Ethnobotany. Timber Press (1998) . ISBN: 978-0881924534
Pharmacopeias & Reviews
- [18] United States Pharmacopeial Convention. USP Dietary Supplements Compendium — Goldenseal (Hydrastis canadensis) Root Powder. United States Pharmacopeia (2023)
Last updated: 2026-03-02 | Status: review
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.